MariMed Inc. · CSE:MRMD
MariMed — Q1 2022 Earnings Presentation
20 slides from MariMed's earnings presentation, May 16, 2022
Slide 1: MariMed May 2022
(MariMed May 2022
Slide 2: MariMed Inc. mission
o-ae<z MariMed Inc. Improve people's lives every day through our products, our.action and our values.
Slide 3: Publicly Traded (OTCQX: MRMD)
o-ae<z Publicly Traded (OTCQX: MRMD OTCQX: MRMD 3
Slide 4: Disciplined Financial Leadership
Disciplined Financial Leadership Sustainable revenues and profits, delivering shareholder value v Disciplined approach to all spending v Track record of consistent revenue and EBITDA growth v One of the strongest EBITDA margins in the industry Clean balance sheet to support growth v Positive operati
Slide 5: Strong Financial Results
Strong Financial Results Quarterly View ‘Annual View Q122 Revenue & Adj. EBITDA growth of 27% and 29%, respectively, YoY Q122 Adj. EBITDA Margin of 33.1% Qi22 Qi21 2021 2020 FY 2021 Revenue & Adj. EBITDA growth of 139% and 144%, |i respectively, YoY 2021 Adj. EBITDA Margin of 35.5% , among highest i
Slide 6: Experienced Leadership Team
Experienced Leadership Team (M ¢ Tenured and validated management team ¢ Strong track record of winning licenses ¢ Portfolio of award-winning brands * Developed >300k SF of cultivation, processing and dispensary facilities * Designed, developed, and implemented SOPs for state-of-the-art cannabis ope
Slide 7: National Footprint in Attractive States
National Footprint in Attractive States 6; 7 | 4}, 5 | 1 States Operating Dispensaries Dispensaries Operational Cultivation Cultivation and Production Under Development and Production Facilities Under Development Maryland Illinois Massachusetts a © 1 Dispensary operational Pa 2 Dispensaries under co
Slide 8: Craft Cannabis At Scale
Craft Cannabis At Scale ¢ Expansive library of world class genetics ¢ Proven agricultural techniques blended with the latest technologies * Personal attention to each plant OTCQX: MRMD
Slide 9: Exceptional Customer Experience at Retail
Exceptional Customer Experience at Retail ¢ Highest quality brands & products ¢ Budtender & retail personnel = SS SBN see training programs ¢ Upscale design & safe environment = BS, * Proprietary technology enables ® —/) Fifi FY Oe faster transaction times L $ ¢ Home delivery in Massachusetts OTCQX:
Slide 10: Trusted Quality Brands & Products
Trusted Quality Brands & Products Nature’s ® ww HERITAGE TIKUN THRIDE CANNABIS trytikun.com (kK) Se esses i i &73 TROPIZEN Vibations ., >, ,, “© ; Wy (H) PANACEA : i HEALER WE KIND OTCQX: MRMD
Slide 11: Building Buzz - World's Largest Pot Brownie
Building Buzz - World's Largest Pot Brown LATE a Ki LIVE stephen LIVES colbert The People — Boston TODAY Globe ADWEEK ecz= Top 5 Cannabis Marketing Moves of 2021 .... And 1,000+ more in 43 countries OTCQX: MRMD u 7
Slide 12: Strategic Plan Focused on Growth Drivers
Strategic Plan Focused on Growth Drivers + 1. ACQUIRE & CONSOLIDATE CLIENT BUSINESSES eee Consolidate existing managed client businesses into public company operations PROGRESS Maryland closed. Consolidated late April. * Delaware TBD (subject to changes in state laws) MY il. INCREASE REVENUE IN EXIS
Slide 13: Strategic Plan Focused on Growth Drivers
Strategic Plan Focused on Growth Drivers - Haz Il. EXPAND FOOTPRINT IN ADDITIONAL STATES Secure new licenses though applications and M&A PROGRESS M&A discussions with businesses in several high-growth states * Won lottery for provisional dispensary license in OH * Supporting new applications in CT,
Slide 14: Potential To More Than Triple Revenue With Existing Footprint
Potential To More Than Triple Revenue WithExisting /(), Footprint? —_ Acquire & Consolidate Client Businesses Est. Annualized Revenue Delaware (TBD) and Maryland (completed) $40M - $65M Maximize Footprint in Existing States Expansion to increase capacity in MA, MD $50M - $85M Add 12 dispensaries: IL
Slide 15: What Differentiates MariMed?
What Differentiates MariMed? =" Tenured and validated leadership team =" Financial discipline, clean balance sheet With positive cash flow =" Developed our own businesses and GOnsolidate ™ Focus on quality — craft cultivation afseale = Portfolio of award-winning brands OTCQX: MRMD
Slide 16: MariMed Selected Financials
MariMed Selected Financials ($000) 2022 2020 2021 Guidance Revenue S 50,895 S$ 121,464 $145M - $150M Gross Profit S 31,325 S$ 66,263 Gross Margin 61.5% 54.6% In-line with 2021 Growth Rates Revenue (Y/Y) 12% 139% Adj. EBITDA S 17,706 $ 43,134 S47M - $52M Ad. EBITDA Margin 34.8% 35.5% Cash On Hand S 2
Slide 17: MariMed Selected Financials
MariMed Selected Financials Three Months Ended March 31, YoY ($ in thousands) 2022 2021 Change (%) Revenues $ 31,282 $ 24,643 27% Gross Profit $ 16,976 $ 13,186 29% Gross Margin 54.3% 53.5% Operating Expenses $ 9927 $ 6,148 61% Non-GAAP Adj. EBITDA‘ $ 10,362 $ 8,033 29% Non-GAAP Adj. EBITDA Margin’
Slide 18: MariMed Capitalization Table
MariMed Capitalization Table (as of Mar 31, 20 (shares in millions) Total Basic Shares Outstanding 335.6 Potentially Dilutive Securities: Series B Preferred Stock 4.9 Series C Preferred Stock 31.1 Issued Options 39.8 Issued Warrants 26.4 Total Potentially Dilutive Shares 102.2 Total Diluted Shares O
Slide 19: Important Disclaimer & Cautions Regarding Forward-Looking Statements
Important Disclaimer & Cautions Regarding Forward-Looking Statements This presentation does not constitute an offer to sell or a solicitation of an offer to buy securities or assets of MariMed Inc. (“MariMed” or the “Company”). All information presented herein with respect to the existing business a
Slide 20: Thank you!
MariMed Inc. r Thank you! Company Contact: Steve West \“S1r@marimedine.com Sho x ¥ bn al bon 20